Table 4.
Phase III Clinical Trials of KIs in Patients with DTC and MTC
Cancer | Study | E/C | HR | PFS (E/C) | Ref. |
---|---|---|---|---|---|
MTC | |||||
Vandetanib (300 mg/d) | Phase III | (231/100) | 0.46a | 30.5/19.3 | 51 |
Cabozantinib (140 mg/d) | Phase III | (219/111) | 0.28b | 11.2/4.0 | 64 |
DTC | |||||
Sorafnib (400 mg/d) | Phase III | (207/210) | 0.58c | 10.8/5.8 | 66 |
Abbreviations: E/C, experimental group/placebo group; HR, hazard ratio.
95% confidence interval (CI), 0.31–0.69; P = .0001.
95% CI, 0.19 to 0.40; P < .001.
95% CI, 0.45–0.75; P < .0001.